|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
188,370,000 |
Market
Cap: |
16.70(B) |
Last
Volume: |
1,778,607 |
Avg
Vol: |
1,398,026 |
52
Week Range: |
$76.22 - $99 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 1018 |
Guru Rank Value : 0.1 |
Guru Occurances : 4 |
|
|
|
|
|
|
|
Company Profile BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
3,625 |
Total Buy Value |
$0 |
$0 |
$0 |
$314,469 |
Total People Bought |
0 |
0 |
0 |
1 |
Total Buy Transactions |
0 |
0 |
0 |
1 |
Total Shares Sold |
714 |
160,302 |
276,407 |
571,147 |
Total Sell Value |
$64,260 |
$13,335,112 |
$23,824,420 |
$53,365,721 |
Total People Sold |
1 |
5 |
6 |
7 |
Total Sell Transactions |
1 |
11 |
22 |
49 |
End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Bienaime Jean Jacques |
Chief Executive Officer |
|
2022-04-18 |
4 |
AS |
$81.91 |
$1,638,200 |
D/D |
(20,000) |
334,983 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2022-04-18 |
4 |
OE |
$37.46 |
$749,200 |
D/D |
20,000 |
354,983 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2022-04-14 |
4 |
AS |
$83.66 |
$836,600 |
D/D |
(10,000) |
334,983 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2022-04-14 |
4 |
OE |
$37.46 |
$374,600 |
D/D |
10,000 |
344,983 |
|
- |
|
Lawlis V Bryan |
Director |
|
2022-04-14 |
4 |
AS |
$83.66 |
$355,555 |
D/D |
(4,250) |
23,970 |
|
- |
|
Lawlis V Bryan |
Director |
|
2022-04-14 |
4 |
OE |
$37.46 |
$159,205 |
D/D |
4,250 |
28,220 |
|
- |
|
Ajer Jeffrey Robert |
EVP, Chief Commercial Officer |
|
2022-04-13 |
4 |
AS |
$82.47 |
$97,315 |
D/D |
(1,180) |
55,077 |
|
- |
|
Ajer Jeffrey Robert |
EVP, Chief Commercial Officer |
|
2022-03-30 |
4 |
AS |
$79.56 |
$109,872 |
D/D |
(1,381) |
56,257 |
|
- |
|
Ajer Jeffrey Robert |
EVP, Chief Commercial Officer |
|
2022-03-29 |
4 |
AS |
$79.43 |
$128,518 |
D/D |
(1,618) |
57,638 |
|
- |
|
Ajer Jeffrey Robert |
EVP, Chief Commercial Officer |
|
2022-03-23 |
4 |
AS |
$81.78 |
$501,230 |
D/D |
(6,129) |
59,256 |
|
- |
|
Ajer Jeffrey Robert |
EVP, Chief Commercial Officer |
|
2022-03-22 |
4 |
AS |
$81.00 |
$167,913 |
D/D |
(2,073) |
65,385 |
|
- |
|
Davis George Eric |
EVP, General Counsel |
|
2022-03-21 |
4 |
AS |
$81.29 |
$498,226 |
D/D |
(6,129) |
63,329 |
|
- |
|
Fuchs Henry J |
President, Worldwide R&D |
|
2022-03-16 |
4 |
D |
$80.72 |
$182,346 |
D/D |
(2,259) |
143,753 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2022-03-16 |
4 |
D |
$80.72 |
$448,803 |
D/D |
(5,560) |
334,983 |
|
- |
|
Ajer Jeffrey Robert |
EVP, Chief Commercial Officer |
|
2022-03-16 |
4 |
D |
$80.72 |
$103,887 |
D/D |
(1,287) |
67,458 |
|
- |
|
Mueller Brian |
EVP, Chief Financial Officer |
|
2022-03-16 |
4 |
D |
$80.72 |
$46,979 |
D/D |
(582) |
38,299 |
|
- |
|
Davis George Eric |
EVP, General Counsel |
|
2022-03-16 |
4 |
D |
$80.72 |
$101,061 |
D/D |
(1,252) |
69,458 |
|
- |
|
Fuchs Henry J |
President, Worldwide R&D |
|
2022-03-15 |
4 |
D |
$78.27 |
$947,145 |
D/D |
(12,101) |
146,012 |
|
- |
|
Fuchs Henry J |
President, Worldwide R&D |
|
2022-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
38,790 |
158,113 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2022-03-15 |
4 |
D |
$78.27 |
$2,998,211 |
D/D |
(38,306) |
340,543 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2022-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
40,280 |
378,849 |
|
- |
|
Ajer Jeffrey Robert |
EVP, Chief Commercial Officer |
|
2022-03-15 |
4 |
D |
$78.27 |
$658,877 |
D/D |
(8,418) |
68,745 |
|
- |
|
Ajer Jeffrey Robert |
EVP, Chief Commercial Officer |
|
2022-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
11,940 |
77,163 |
|
- |
|
Mueller Brian |
EVP, Chief Financial Officer |
|
2022-03-15 |
4 |
D |
$78.27 |
$146,208 |
D/D |
(1,868) |
38,881 |
|
- |
|
Mueller Brian |
EVP, Chief Financial Officer |
|
2022-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
11,040 |
40,749 |
|
- |
|
1286 Records found
|
|
Page 10 of 52 |
|
|